Clinical responses were retrospectively observed in patients with stage III and IV melanoma that were treated with ipilimumab upon disease progression, after receiving at least 3 bi-weekly vaccinations with gp100 and tyrosinase-loaded DCs.105. This evidence concerns the gene PMEL and melanoma.